Global Q Fever Market Research Report Forecast to 2023

Array
(
    [id] => 1673495
    [discount] => PDF-18-ENTERPRISE WIDE LICENCE-20------
    [isbn] => 
    [title] => Global Q Fever Market Research Report Forecast to 2023
    [upcommingtext] => 
    [seo_url] => global-q-fever-market-research-report-forecast
    [shortdesc] => 
    [meta_title] => Global Q Fever Market Research Report Forecast to 2023
    [keyword] => Global Q Fever Market Research Report Forecast to 2023
    [description] => Introduction
Q fever is a mild disease with flu-like symptoms. In Q fever, the infection is caused by the bacterium Coxiella burnetii. Many patients have no symptoms at all, while, in
    [curr] => USD
    [category] => 1200
    [publisher] => 182
    [published_date] => 2019-06-30
    [country] => 230
    [author_name] => 
    [page_num] => 105
    [abstract] => Introduction
Q fever is a mild disease with flu-like symptoms. In Q fever, the infection is caused by the bacterium Coxiella burnetii. Many patients have no symptoms at all, while, in some cases, the infection could reoccur/resurface years later. Chronic Q fever may damage the heart, liver, brain, lungs, and could cause diabetes in some cases.
The major factors driving the growth of the market include rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in risk factors of Q fever, and globally growing geriatric population.
The global Q fever market has been segmented on the basis of type, diagnosis, treatment, end user, and region.
The global Q fever market, by type, has been segmented into acute and chronic.
The global Q fever market, by diagnosis, has been segmented into serology tests and others.
The global Q fever market, by treatment, has been segmented into antibiotics and surgery.
The global Q fever market, by end user, has been segmented into patients, hospitals and clinics, and others.
The global Q fever market is expected to reach a market value of USD 9,850.65 million by 2023 from USD 6,249.68 million in 2017 and is expected to register a CAGR of 7.83% during the forecast period of 2018 to 2023. In 2017, Asia-Pacific held the highest share of the market at 44.9%, followed by the Middle East and Africa with a share of 25.4%.


Key Players
Merck KGaA, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Basilea Pharmaceutica Ltd, Sanofi S. A., Melinta Therapeutics, Inc., Bayer AG, Johnson & Johnson Services, Inc., Yashica Pharmaceuticals, and AtoxBio.
Study Objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Q fever market
• To provide insights into factors affecting the market growth
• To analyze the global Q fever market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by type, diagnosis, treatment, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Q fever market
Target Audience
• Hospitals
• Q fever Companies
• Associations and Organizations
Key Findings
• The global Q fever market is expected to reach USD 9,850.65 million by 2023 at a CAGR of 7.83% from 2018 to 2023
• On the basis of type, the chronic segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.33% during the forecast period
• On the basis of diagnosis, the serology tests segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.32% during the forecast period
• On the basis of treatment, the antibiotics segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.32% during the forecast period
• On the basis of end user, the patients segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.21% during the forecast period
Regional Analysis
• Americas
o North America
 US
 Canada
o Latin America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o UAE
o Saudi Arabia
o Oman
o Kuwait
o Qatar
o Africa
o Rest of the Middle East & Africa

[table_of_contents] =>

1 Report prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Worldwide Rising Prevalence of Q fever Coupled with Increasing Q Fever Hospitalization Rates
4.2.2 Rising Worldwide Cattle, Sheep, and Goat Population
4.2.3 Growth in the Risk Factors of Q Fever
4.2.4 Globally Growing Geriatric Population
4.3 Restraints
4.3.1 High Cost of Diagnostic Tests
4.3.2 Lack of Awareness About Q Fever
4.4 Opportunity
4.4.1 Presence of Untapped Opportunities in the Asia-Pacific and African Regions
4.5 Market Trends
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Rivalry
5.2 Supply Chain Analysis
5.2.1 R&D and Development
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6 Global Q Fever Market, By Type
6.1 Overview
6.2 Acute
6.3 Chronic
7 Global Q Fever Market, By Diagnosis
7.1 Overview
7.2 Serology Tests
7.3 Others
8 Global Q Fever Market, By Treatment
8.1 Overview
8.2 Antibiotics
8.3 Surgery
9 Global Q Fever Market, By End-User
9.1 Overview
9.2 Patients
9.3 Hospitals
9.4 Others
10 Global Q Fever Market, By Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 UAE
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Africa
10.5.7 Rest of Middle East & Africa
11 Company Profile
11.1 Merck KGaA
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 SWOT Analysis
11.1.5 Key Developments
11.1.6 Key Strategies
11.2 Teva Pharmaceutical Industries Ltd
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Pfizer Inc.
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 SWOT Analysis
11.3.5 Key Developments
11.3.6 Key Strategies
11.4 Basilea Pharmaceutica Ltd
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 Sanofi S. A.
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 SWOT Analysis
11.5.5 Key Developments
11.5.6 Key strategies
11.6 Melinta Therapeutics, Inc.
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 Bayer AG
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 SWOT Analysis
11.7.5 Key Developments
11.7.6 Key Strategies
11.8 Johnson & Johnson Services, Inc.
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offered
11.8.4 SWOT Analysis
11.8.5 Key Developments
11.8.6 Key Strategies
11.9 Yashica Pharmaceuticals
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.1 AtoxBio
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
12 Appendix
12.1 Discussion Blue Print [list_of_tables] =>

TABLE 1 PRIMARY INTERVIEWS
TABLE 2 TREATMENT COST FOR THE Q FEVER
TABLE 3 GLOBAL Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 4 GLOBAL Q FEVER MARKET, FOR ACUTE BY REGION, 2015–2023 (USD THOUSAND)
TABLE 5 GLOBAL Q FEVER MARKET, FOR CHRONIC BY REGION, 2015–2023 (USD THOUSAND)
TABLE 6 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 7 GLOBAL Q FEVER MARKET, FOR SEROLOGY TESTS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 8 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 9 GLOBAL Q FEVER MARKET, FOR ANTIBIOTICS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 10 GLOBAL Q FEVER MARKET, FOR SURGERY BY REGION, 2015–2023 (USD THOUSAND)
TABLE 11 GLOBAL Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 12 GLOBAL Q FEVER MARKET, FOR PATIENTS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 13 GLOBAL Q FEVER MARKET, FOR HOSPITALS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 14 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2015–2023 (USD THOUSAND)
TABLE 15 GLOBAL Q FEVER MARKET, BY REGION, 2015–2023 (USD THOUSAND)
TABLE 16 AMERICAS: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 17 AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 18 AMERICAS: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 19 AMERICAS: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 20 NORTH AMERICA: Q FEVER MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 21 NORTH AMERICAS: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 22 NORTH AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 23 NORTH AMERICAS: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 24 NORTH AMERICAS: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 25 US: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 26 US: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 27 US: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 28 US: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 29 CANADA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 30 CANADA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 31 CANADA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 32 CANADA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 33 LATIN AMERICA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 34 LATIN AMERICA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 35 LATIN AMERICA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 36 LATIN AMERICA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 37 EUROPE: Q FEVER MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 38 EUROPE: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 39 EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 40 EUROPE: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 41 EUROPE: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 42 GERMANY: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 43 GERMANY: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 44 GERMANY: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 45 GERMANY: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 46 FRANCE: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 47 FRANCE: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 48 FRANCE: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 49 FRANCE: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 50 UK: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 51 UK: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 52 UK: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 53 UK: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 54 ITALY: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 55 ITALY: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 56 ITALY: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 57 ITALY: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 58 SPAIN: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 59 SPAIN: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 60 SPAIN: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 61 SPAIN: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 62 REST OF EUROPE: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 63 REST OF EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 64 REST OF EUROPE: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 65 REST OF EUROPE: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC: Q FEVER MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 71 JAPAN: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 72 JAPAN: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 73 JAPAN: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 74 JAPAN: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 75 CHINA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 76 CHINA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 77 CHINA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 78 CHINA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 79 INDIA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 80 INDIA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 81 INDIA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 82 INDIA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 83 AUSTRALIA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 84 AUSTRALIA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 85 AUSTRALIA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 86 AUSTRALIA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 87 SOUTH KOREA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 88 SOUTH KOREA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 89 SOUTH KOREA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 90 SOUTH KOREA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 91 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 92 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 93 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 94 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 95 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 96 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 97 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 98 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 99 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 100 UAE: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 101 UAE: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 102 UAE: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 103 UAE: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 104 SAUDI ARABIA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 105 SAUDI ARABIA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 106 SAUDI ARABIA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 107 SAUDI ARABIA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 108 OMAN: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 109 OMAN: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 110 OMAN: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 111 OMAN: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 112 KUWAIT: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 113 KUWAIT: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 114 KUWAIT: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 115 KUWAIT: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 116 QATAR: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 117 QATAR: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 118 QATAR: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 119 QATAR: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 120 AFRICA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 121 AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 122 AFRICA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 123 AFRICA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND)
TABLE 124 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2015–2023 (USD THOUSAND)
TABLE 125 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015–2023 (USD THOUSAND)
TABLE 126 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
TABLE 127 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2015–2023 (USD THOUSAND) [list_of_figures] =>

FIGURE 1 GLOBAL Q FEVER MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL Q FEVER MARKET
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL Q FEVER MARKET
FIGURE 6 SUPPLY CHAIN: GLOBAL Q FEVER MARKET
FIGURE 7 GLOBAL Q FEVER MARKET SHARE, BY TYPE, 2017 (%)
FIGURE 8 GLOBAL Q FEVER MARKET, BY TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 9 GLOBAL Q FEVER MARKET SHARE, BY DIAGNOSIS, 2017 (%)
FIGURE 10 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2017 & 2023 (USD THOUSAND)
FIGURE 11 GLOBAL Q FEVER MARKET, BY TREATMENT, 2015–2023 (USD THOUSAND)
FIGURE 12 GLOBAL Q FEVER MARKET SHARE, BY TREATMENT, 2017 (%)
FIGURE 13 GLOBAL Q FEVER MARKET, BY TREATMENT, 2017 & 2023 (USD THOUSAND)
FIGURE 14 GLOBAL Q FEVER MARKET SHARE, BY END USER, 2017 (%)
FIGURE 15 GLOBAL Q FEVER MARKET, BY END USER, 2017 & 2023 (USD THOUSAND)
FIGURE 16 GLOBAL Q FEVER MARKET SHARE, BY REGION, 2017 (%)
FIGURE 17 AMERICAS: Q FEVER MARKET SHARE, BY REGION, 2017 (%)
FIGURE 18 NORTH AMERICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 19 EUROPE: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 20 ASIA-PACIFIC: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 21 MIDDLE EAST & AFRICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%) [sample_page] => [brochure] => [new_price] => PDF-4450-ENTERPRISE WIDE LICENCE-6250-SITE LICENCE--ENTERPRISE WIDE LICENCE--Enterprise Wide Licence--Enterprise Wide Licence--Multi User Licence- )
discount aarkstore
Introduction
Q fever is a mild disease with flu-like symptoms. In Q fever, the infection is caused by the bacterium Coxiella burnetii. Many patients have no symptoms at all, while, in some cases, the infection could reoccur/resurface years later. Chronic Q fever may damage the heart, liver, brain, lungs, and could cause diabetes in some cases.
The major factors driving the growth of the market include rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in risk factors of Q fever, and globally growing geriatric population.
The global Q fever market has been segmented on the basis of type, diagnosis, treatment, end user, and region.
The global Q fever market, by type, has been segmented into acute and chronic.
The global Q fever market, by diagnosis, has been segmented into serology tests and others.
The global Q fever market, by treatment, has been segmented into antibiotics and surgery.
The global Q fever market, by end user, has been segmented into patients, hospitals and clinics, and others.
The global Q fever market is expected to reach a market value of USD 9,850.65 million by 2023 from USD 6,249.68 million in 2017 and is expected to register a CAGR of 7.83% during the forecast period of 2018 to 2023. In 2017, Asia-Pacific held the highest share of the market at 44.9%, followed by the Middle East and Africa with a share of 25.4%.


Key Players
Merck KGaA, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Basilea Pharmaceutica Ltd, Sanofi S. A., Melinta Therapeutics, Inc., Bayer AG, Johnson & Johnson Services, Inc., Yashica Pharmaceuticals, and AtoxBio.
Study Objectives
To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Q fever market
To provide insights into factors affecting the market growth
To analyze the global Q fever market based on various tools such as supply chain analysis and Porters five force analysis
To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
To provide country-level analysis of the market with respect to the current market size and future perspective
To provide country-level analysis of the market for segments by type, diagnosis, treatment, end user, and region
To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Q fever market
Target Audience
Hospitals
Q fever Companies
Associations and Organizations
Key Findings
The global Q fever market is expected to reach USD 9,850.65 million by 2023 at a CAGR of 7.83% from 2018 to 2023
On the basis of type, the chronic segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.33% during the forecast period
On the basis of diagnosis, the serology tests segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.32% during the forecast period
On the basis of treatment, the antibiotics segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.32% during the forecast period
On the basis of end user, the patients segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.21% during the forecast period
Regional Analysis
Americas
oNorth America
US
Canada
oLatin America
Europe
oGermany
oFrance
oUK
oItaly
oSpain
oRest of Europe
Asia-Pacific
oJapan
oChina
oIndia
oAustralia
oRepublic of Korea
oRest of Asia-Pacific
Middle East & Africa
oUAE
oSaudi Arabia
oOman
oKuwait
oQatar
oAfrica
oRest of the Middle East & Africa



1Report prologue
2Market Introduction
2.1Definition
2.2Scope of the Study
2.3Assumptions & Limitations
2.3.1Assumptions
2.3.2Limitations
2.4Market Structure
3Research Methodology
3.1Research Process
3.2Primary Research
3.3Secondary Research
3.4Market Size Estimation
3.5Forecast Model
4Market Dynamics
4.1Introduction
4.2Drivers
4.2.1Worldwide Rising Prevalence of Q fever Coupled with Increasing Q Fever Hospitalization Rates
4.2.2Rising Worldwide Cattle, Sheep, and Goat Population
4.2.3Growth in the Risk Factors of Q Fever
4.2.4Globally Growing Geriatric Population
4.3Restraints
4.3.1High Cost of Diagnostic Tests
4.3.2Lack of Awareness About Q Fever
4.4Opportunity
4.4.1Presence of Untapped Opportunities in the Asia-Pacific and African Regions
4.5Market Trends
4.6Macroeconomic Indicators
5Market Factor Analysis
5.1Porters Five Forces Model
5.1.1Bargaining Power of Suppliers
5.1.2Bargaining Power of Buyers
5.1.3Threat of New Entrants
5.1.4Threat of Substitutes
5.1.5Rivalry
5.2Supply Chain Analysis
5.2.1R&D and Development
5.2.2Manufacturing
5.2.3Distribution & Sales
5.2.4Post-Sales Monitoring
5.3Investment Feasibility Analysis
5.4Pricing Analysis
6Global Q Fever Market, By Type
6.1Overview
6.2Acute
6.3Chronic
7Global Q Fever Market, By Diagnosis
7.1Overview
7.2Serology Tests
7.3Others
8Global Q Fever Market, By Treatment
8.1Overview
8.2Antibiotics
8.3Surgery
9Global Q Fever Market, By End-User
9.1Overview
9.2Patients
9.3Hospitals
9.4Others
10Global Q Fever Market, By Region
10.1Overview
10.2Americas
10.2.1North America
10.2.1.1US
10.2.1.2Canada
10.2.2Latin America
10.3Europe
10.3.1Germany
10.3.2France
10.3.3UK
10.3.4Italy
10.3.5Spain
10.3.6Rest of Europe
10.4Asia-Pacific
10.4.1Japan
10.4.2China
10.4.3India
10.4.4Australia
10.4.5South Korea
10.4.6Rest of Asia-Pacific
10.5Middle East & Africa
10.5.1UAE
10.5.2Saudi Arabia
10.5.3Oman
10.5.4Kuwait
10.5.5Qatar
10.5.6Africa
10.5.7Rest of Middle East & Africa
11Company Profile
11.1Merck KGaA
11.1.1Company Overview
11.1.2Financial Overview
11.1.3Products/Services Offered
11.1.4SWOT Analysis
11.1.5Key Developments
11.1.6Key Strategies
11.2Teva Pharmaceutical Industries Ltd
11.2.1Company Overview
11.2.2Financial Overview
11.2.3Products/Services Offered
11.2.4Key Developments
11.2.5SWOT Analysis
11.2.6Key Strategies
11.3Pfizer Inc.
11.3.1Company Overview
11.3.2Financial Overview
11.3.3Products/Services Offered
11.3.4SWOT Analysis
11.3.5Key Developments
11.3.6Key Strategies
11.4Basilea Pharmaceutica Ltd
11.4.1Company Overview
11.4.2Financial Overview
11.4.3Products/Services Offered
11.4.4Key Developments
11.4.5SWOT Analysis
11.4.6Key Strategies
11.5Sanofi S. A.
11.5.1Company Overview
11.5.2Financial Overview
11.5.3Products/Services Offered
11.5.4SWOT Analysis
11.5.5Key Developments
11.5.6Key strategies
11.6Melinta Therapeutics, Inc.
11.6.1Company Overview
11.6.2Financial Overview
11.6.3Products/Services Offered
11.6.4Key Developments
11.6.5SWOT Analysis
11.6.6Key Strategies
11.7Bayer AG
11.7.1Company Overview
11.7.2Financial Overview
11.7.3Products/Services Offered
11.7.4SWOT Analysis
11.7.5Key Developments
11.7.6Key Strategies
11.8Johnson & Johnson Services, Inc.
11.8.1Company Overview
11.8.2Financial Overview
11.8.3Products/Services Offered
11.8.4SWOT Analysis
11.8.5Key Developments
11.8.6Key Strategies
11.9Yashica Pharmaceuticals
11.9.1Company Overview
11.9.2Financial Overview
11.9.3Products/Services Offered
11.9.4Key Developments
11.9.5SWOT Analysis
11.9.6Key Strategies
11.1AtoxBio
11.10.1Company Overview
11.10.2Financial Overview
11.10.3Products/Services Offered
11.10.4Key Developments
11.10.5SWOT Analysis
11.10.6Key Strategies
12Appendix
12.1Discussion Blue Print

List Of Tables



TABLE 1PRIMARY INTERVIEWS
TABLE 2TREATMENT COST FOR THE Q FEVER
TABLE 3GLOBAL Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 4GLOBAL Q FEVER MARKET, FOR ACUTE BY REGION, 20152023 (USD THOUSAND)
TABLE 5GLOBAL Q FEVER MARKET, FOR CHRONIC BY REGION, 20152023 (USD THOUSAND)
TABLE 6GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 7GLOBAL Q FEVER MARKET, FOR SEROLOGY TESTS BY REGION, 20152023 (USD THOUSAND)
TABLE 8GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 20152023 (USD THOUSAND)
TABLE 9GLOBAL Q FEVER MARKET, FOR ANTIBIOTICS BY REGION, 20152023 (USD THOUSAND)
TABLE 10GLOBAL Q FEVER MARKET, FOR SURGERY BY REGION, 20152023 (USD THOUSAND)
TABLE 11GLOBAL Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 12GLOBAL Q FEVER MARKET, FOR PATIENTS BY REGION, 20152023 (USD THOUSAND)
TABLE 13GLOBAL Q FEVER MARKET, FOR HOSPITALS BY REGION, 20152023 (USD THOUSAND)
TABLE 14GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 20152023 (USD THOUSAND)
TABLE 15GLOBAL Q FEVER MARKET, BY REGION, 20152023 (USD THOUSAND)
TABLE 16AMERICAS: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 17AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 18AMERICAS: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 19AMERICAS: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 20NORTH AMERICA: Q FEVER MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 21NORTH AMERICAS: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 22NORTH AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 23NORTH AMERICAS: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 24NORTH AMERICAS: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 25US: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 26US: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 27US: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 28US: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 29CANADA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 30CANADA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 31CANADA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 32CANADA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 33LATIN AMERICA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 34LATIN AMERICA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 35LATIN AMERICA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 36LATIN AMERICA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 37EUROPE: Q FEVER MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 38EUROPE: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 39EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 40EUROPE: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 41EUROPE: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 42GERMANY: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 43GERMANY: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 44GERMANY: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 45GERMANY: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 46FRANCE: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 47FRANCE: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 48FRANCE: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 49FRANCE: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 50UK: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 51UK: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 52UK: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 53UK: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 54ITALY: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 55ITALY: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 56ITALY: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 57ITALY: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 58SPAIN: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 59SPAIN: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 60SPAIN: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 61SPAIN: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 62REST OF EUROPE: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 63REST OF EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 64REST OF EUROPE: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 65REST OF EUROPE: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 66ASIA-PACIFIC: Q FEVER MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 67ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 68ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 69ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 70ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 71JAPAN: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 72JAPAN: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 73JAPAN: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 74JAPAN: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 75CHINA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 76CHINA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 77CHINA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 78CHINA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 79INDIA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 80INDIA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 81INDIA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 82INDIA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 83AUSTRALIA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 84AUSTRALIA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 85AUSTRALIA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 86AUSTRALIA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 87SOUTH KOREA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 88SOUTH KOREA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 89SOUTH KOREA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 90SOUTH KOREA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 91REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 92REST OF ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 93REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 94REST OF ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 95MIDDLE EAST & AFRICA: Q FEVER MARKET, BY COUNTRY, 20152023 (USD THOUSAND)
TABLE 96MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 97MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 98MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 99MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 100UAE: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 101UAE: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 102UAE: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 103UAE: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 104SAUDI ARABIA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 105SAUDI ARABIA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 106SAUDI ARABIA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 107SAUDI ARABIA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 108OMAN: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 109OMAN: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 110OMAN: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 111OMAN: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 112KUWAIT: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 113KUWAIT: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 114KUWAIT: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 115KUWAIT: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 116QATAR: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 117QATAR: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 118QATAR: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 119QATAR: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 120AFRICA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 121AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 122AFRICA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 123AFRICA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)
TABLE 124REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 20152023 (USD THOUSAND)
TABLE 125REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 20152023 (USD THOUSAND)
TABLE 126REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
TABLE 127REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 20152023 (USD THOUSAND)

List Of Figures



FIGURE 1GLOBAL Q FEVER MARKET: MARKET STRUCTURE
FIGURE 2RESEARCH PROCESS
FIGURE 3TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4MARKET DYNAMICS: ANALYSIS OF THE GLOBAL Q FEVER MARKET
FIGURE 5PORTERS FIVE FORCES ANALYSIS: GLOBAL Q FEVER MARKET
FIGURE 6SUPPLY CHAIN: GLOBAL Q FEVER MARKET
FIGURE 7GLOBAL Q FEVER MARKET SHARE, BY TYPE, 2017 (%)
FIGURE 8GLOBAL Q FEVER MARKET, BY TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 9GLOBAL Q FEVER MARKET SHARE, BY DIAGNOSIS, 2017 (%)
FIGURE 10GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2017 & 2023 (USD THOUSAND)
FIGURE 11GLOBAL Q FEVER MARKET, BY TREATMENT, 20152023 (USD THOUSAND)
FIGURE 12GLOBAL Q FEVER MARKET SHARE, BY TREATMENT, 2017 (%)
FIGURE 13GLOBAL Q FEVER MARKET, BY TREATMENT, 2017 & 2023 (USD THOUSAND)
FIGURE 14GLOBAL Q FEVER MARKET SHARE, BY END USER, 2017 (%)
FIGURE 15GLOBAL Q FEVER MARKET, BY END USER, 2017 & 2023 (USD THOUSAND)
FIGURE 16GLOBAL Q FEVER MARKET SHARE, BY REGION, 2017 (%)
FIGURE 17AMERICAS: Q FEVER MARKET SHARE, BY REGION, 2017 (%)
FIGURE 18NORTH AMERICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 19EUROPE: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 20ASIA-PACIFIC: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 21MIDDLE EAST & AFRICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)

2020 Global Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Americas, EMEA, APAC--A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation

This new 68-country report is available by region, country, market segment, section, or individual test. The report is designed to help current suppliers and potential market entrants identify and

USD 45000 View Report

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027 market research report available in single user pdf license with Aarkstore Enterprise at USD 4950

USD 4950 View Report

Global Queuing System Market Research Report 2020-2024

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Queuing System Report by Material, Application, and Geography

USD 2850 View Report

Global Quartz Kitchen Countertops Market Research Report 2020-2024

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Quartz Kitchen Countertops Report by Material, Application, and

USD 2850 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available